Provectus Pharma (PVCT) 2.3200 $PVCT Provectus

Provectus Pharma (PVCT) 2.3200 $PVCT

Provectus Biopharmaceuticals expects US FDA's Breakthrough Therapy Designation for PV-10 for melanoma within 60 days of receipt of application
M2 - Tue Mar 25, 6:14AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC VCT) said on Monday that it has submitted an application for PV-10 for the treatment of melanoma under the US FDA's Breakthrough Therapy Designation (BTD).

Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
Business Wire - Mon Mar 24, 5:05AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that the Agency will make a decision on the application within 60 days of receipt. The Agency's records for FY 2013 show that the Agency's Center for Drug Evaluation and Research (CDER) met that guideline 97% of the time.

Provectus names Dr Joseph M. Chalil to strategic advisory board
M2 - Thu Mar 20, 8:20AM CDT
Oncology company Provectus Biopharmaceuticals (Other OTC VCT) disclosed on Wednesday that Dr Joseph M. Chalil, MD, MBA, FACHE, has been elected to its strategic advisory board.

Provectus names Dr Joseph M. Chalil to Strategic Advisory Board
M2 - Wed Mar 19, 8:34AM CDT
Provectus Biopharmaceuticals, Inc. (OTC: PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced the appointment of Dr Joseph M. Chalil to its strategic advisory board.

Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Mar 13, 11:04AM CDT
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.

Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.

TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG
ACCESSWIRE - Mon Feb 03, 11:27PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Thu Jan 30, 8:47AM CST
Tranzbyte Corp. (OTCPINK: ERBB) was forced to take back the good news that it had struck a deal with a medical-marijuana dispensary to use the dispensary units it sells.

CORRECTION: Provectus's PV-10 path to initial approval in US now clear per FDA meeting minutes
M2 - Tue Jan 28, 9:11AM CST
Correction to headline: Provectus Biopharmaceuticals Inc (OTC VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday that it received the official minutes from a Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.

Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.

Provectus announces clearance of initial approval for PV-10 in US
M2 - Mon Jan 27, 6:23AM CST
Provectus Biopharmaceuticals Inc (OTC VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday the receipt of the official minutes from the Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.

Fisking Provectus' Claims About PV-10's FDA Approval Path
at The Street - Fri Jan 24, 12:41PM CST
Another update to the Provectus PV-10 melanoma drug story.

Provectus Still Won't Answer Key Questions About Skin Cancer Drug PV-10
at The Street - Fri Jan 24, 10:49AM CST
An update to my earlier story about the obsolescence of Provectus' skin-cancer drug PV-10, including some new information about an ongoing study at the Moffitt Cancer Center.

Provectus' Wild Volume Ride Ends With 64.18% Loss for the Day: Provectus Pharmaceutical Inc. (OTCQB: PVCT), Royal Dutch Shell Plc (OTCQB: RYDAF), Fannie Mae (OTCQB: FNMA)
ACCESSWIRE - Fri Jan 24, 8:32AM CST
Despite rumors of impending good news, a favorable research report and herculean stock volume, Provectus Pharmaceutical Inc.'s (OTCQB: PVCT) stock lost 64.18% of its value when the market closed Jan. 23.

The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly
at The Street - Thu Jan 23, 10:26AM CST
Provectus' PV-10 has already been marginalized by better, more powerful skin cancer therapies.

Provectus Pharmaceuticals, Inc. Analyst Research Report
PR Newswire - Wed Jan 22, 6:00AM CST
Provectus Pharmaceuticals (OTC: PVCT), Inc., is a development-stage pharmaceutical company, that engages in developing pharmaceuticals for oncology and dermatology indications. The company's product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis; and PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. In addition, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.